Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1936385

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1936385

U.S. Preeclampsia Laboratory Testing Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 104 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 2500
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 3500
Printable PDF & Excel (Enterprise License above 5 users)
USD 4500

Add to Cart

Description

Table of Contents

The U.S. Preeclampsia Laboratory Testing Market is experiencing notable growth as healthcare providers increasingly focus on early diagnosis and management of preeclampsia-a serious hypertensive disorder affecting pregnant women. The condition, if left undetected, can result in severe complications for both mother and child, making timely laboratory testing essential. In response to rising awareness, technological advancements, and the growing prevalence of high-risk pregnancies, the U.S. market for preeclampsia laboratory testing is projected to reach USD 1.1 billion by 2026 and is expected to expand to USD 1.8 billion by 2033, representing a compound annual growth rate (CAGR) of 6.70%.

Market Insights

Laboratory testing for preeclampsia has progressed significantly over the years. Modern diagnostics include both urine and blood-based tests, allowing for the detection of proteinuria, kidney and liver function abnormalities, and specific biomarkers associated with preeclampsia. These tests not only help identify the condition early but also assist healthcare professionals in monitoring its severity.

Technological advancements such as immunoassays, high-throughput screening, and multiplex testing panels have enhanced the accuracy and speed of preeclampsia diagnosis. Combined with the adoption of point-of-care testing solutions, these innovations are helping clinicians provide timely interventions, reducing maternal and neonatal risks.

Furthermore, increasing incidences of preeclampsia, particularly among women with pre-existing conditions like hypertension, diabetes, or obesity, underscore the growing need for reliable diagnostic solutions. The integration of laboratory testing into standard prenatal care protocols has become critical in managing high-risk pregnancies effectively.

Market Drivers

Several factors are fueling the growth of the U.S. preeclampsia laboratory testing market. One of the primary drivers is growing awareness of maternal health complications among healthcare professionals and patients alike. Prenatal care programs now emphasize early screening and regular monitoring, prompting higher adoption of laboratory tests.

Technological innovation is another key driver. Advanced diagnostic platforms, including enzyme-linked immunosorbent assays (ELISA), biomarker panels, and rapid point-of-care devices, have improved both sensitivity and specificity in detecting preeclampsia. This has made early detection more feasible and reliable, enabling proactive management.

Government initiatives and public health programs focusing on maternal and child health are also supporting market growth. Funding for prenatal diagnostic testing, insurance coverage, and awareness campaigns have collectively encouraged hospitals and diagnostic laboratories to incorporate advanced preeclampsia testing solutions.

The rising number of high-risk pregnancies, influenced by delayed childbirth, obesity, and lifestyle-related health conditions, has further amplified demand for preeclampsia diagnostic tests. As the patient pool grows, the need for frequent monitoring and advanced testing continues to rise, supporting sustained market expansion.

Business Opportunities

The U.S. preeclampsia laboratory testing market presents ample opportunities for both established and emerging diagnostic companies. Innovations in biomarker detection, multiplex assays, and rapid diagnostics are expected to drive adoption across hospitals, clinics, and diagnostic centers.

Collaborations between diagnostic companies and healthcare providers can enhance market penetration. Investment in research and development to discover novel biomarkers and create more precise testing platforms will likely provide a competitive edge. Moreover, integrating digital solutions, such as telemedicine-enabled reporting and remote monitoring, can streamline testing processes and improve patient care.

Regional Analysis

The United States dominates the North American preeclampsia laboratory testing market due to its advanced healthcare infrastructure, high awareness levels, and availability of cutting-edge diagnostic technologies. Key regions contributing to market growth include California, Texas, New York, and Florida, which host a concentration of tertiary care hospitals and maternal health centers.

Urban centers continue to adopt laboratory testing at a faster pace, while suburban and rural areas are gradually catching up thanks to government-funded prenatal programs and mobile diagnostic initiatives. These efforts are expected to improve market reach and patient access over the forecast period, reducing regional disparities in healthcare services.

Key Players

The U.S. preeclampsia laboratory testing market is highly competitive, with leading companies focusing on product innovation, strategic partnerships, and research initiatives. Prominent market participants include:

  • DiabetOmics
  • DRG Instruments GmbH
  • F. Hoffmann-La Roche Ltd.
  • GestVision, Inc.
  • Lifeassay Diagnostics (Pty) Ltd.
  • Metabolomic Diagnostics
  • Perkin Elmer, Inc.
  • Progenity, Inc.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

These companies are leveraging advanced diagnostic technologies and biomarker research to maintain a strong presence in the market while addressing the growing needs of prenatal healthcare providers and patients.

Market Segmentation

The U.S. preeclampsia laboratory testing market can be segmented to provide a comprehensive understanding of its dynamics:

By Test Type:

  • Urine Tests
  • Blood Tests

By Preeclampsia Type:

  • Mild Preeclampsia
  • Severe Preeclampsia

By End User:

  • Hospitals and Clinics
  • Diagnostic Centres
  • Others

By Region:

  • U.S.
Show more

Table of Contents

1. Executive Summary

  • 1.1. U.S. Preeclampsia Laboratory Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Fiver Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 3.1. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Urine Tests
    • 3.1.2. Blood Tests
  • 3.2. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 3.2.1. Mild Preeclampsia
    • 3.2.2. Severe Preeclampsia
  • 3.3. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals and Clinics
    • 3.3.2. Diagnostic Centres
    • 3.3.3. Others
  • 3.4. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 4.1. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Urine Tests
    • 4.1.2. Blood Tests
  • 4.2. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 4.2.1. Mild Preeclampsia
    • 4.2.2. Severe Preeclampsia
  • 4.3. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centres
    • 4.3.3. Others
  • 4.4. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 4.4.3. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 4.4.6. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 5.1. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Urine Tests
    • 5.1.2. Blood Tests
  • 5.2. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 5.2.1. Mild Preeclampsia
    • 5.2.2. Severe Preeclampsia
  • 5.3. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals and Clinics
    • 5.3.2. Diagnostic Centres
    • 5.3.3. Others
  • 5.4. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.3. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.6. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.9. France U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.12. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.15. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.18. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.21. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Urine Tests
    • 6.1.2. Blood Tests
  • 6.2. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 6.2.1. Mild Preeclampsia
    • 6.2.2. Severe Preeclampsia
  • 6.3. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals and Clinics
    • 6.3.2. Diagnostic Centres
    • 6.3.3. Others
  • 6.4. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.3. China U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.6. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.9. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.12. India U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.15. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.18. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 7.1. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Urine Tests
    • 7.1.2. Blood Tests
  • 7.2. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 7.2.1. Mild Preeclampsia
    • 7.2.2. Severe Preeclampsia
  • 7.3. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Diagnostic Centres
    • 7.3.3. Others
  • 7.4. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.3. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.6. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.9. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.12. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Urine Tests
    • 8.1.2. Blood Tests
  • 8.2. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 8.2.1. Mild Preeclampsia
    • 8.2.2. Severe Preeclampsia
  • 8.3. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals and Clinics
    • 8.3.2. Diagnostic Centres
    • 8.3.3. Others
  • 8.4. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.3. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.6. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.9. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.12. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.15. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. DiabetOmics
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. DRG Instruments GmbH
    • 9.4.3. F. Hoffmann-La Roche Ltd.
    • 9.4.4. GestVision, Inc.
    • 9.4.5. Lifeassay Diagnostics (Pty) Ltd.
    • 9.4.6. Metabolomic Diagnostics
    • 9.4.7. Perkin Elmer, Inc.
    • 9.4.8. Progenity, Inc.
    • 9.4.9. Quidel Corporation
    • 9.4.10. Siemens Healthineers

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!